Serum 25-hydroxyvitamin D response to vitamin D3 supplementation 50,000 IU monthly in youth with HIV-1 infection

Peter L. Havens, Kathleen Mulligan, Rohan Hazra, Patricia Flynn, Brandy Rutledge, Marta D. Van Loan, Jorge Lujan-Zilbermann, Bill G. Kapogiannis, Craig M. Wilson, Charles B. Stephensen, [No Value] Emmanuel, [No Value] Lujan-Zilberman, [No Value] Julian, [No Value] Belzer, [No Value] Flores, [No Value] Tucker, [No Value] Kovacs, [No Value] Homans, [No Value] Lozano, [No Value] D'Angelo[No Value] Hagler, [No Value] Trexler, [No Value] Douglas, [No Value] Tanney, [No Value] DiBenedetto, [No Value] Martinez, [No Value] Bojan, [No Value] Jackson, [No Value] Febo, [No Value] Ayala-Flores, [No Value] Fuentes-Gomez, [No Value] Futterman, [No Value] Enriquez-Bruce, [No Value] Campos, [No Value] Steever, [No Value] Geiger, [No Value] Moscicki, [No Value] Auerswald, [No Value] Irish, [No Value] Abdalian, [No Value] Kozina, [No Value] Baker, [No Value] Peralta, [No Value] Gorle, [No Value] Friedman, [No Value] Maturo, [No Value] Major-Wilson, [No Value] Puga, [No Value] Leonard, [No Value] Inman, [No Value] Flynn, [No Value] Dillard, [No Value] Garofalo, [No Value] Brennan, [No Value] Flanagan

Research output: Contribution to journalArticlepeer-review

39 Scopus citations


Context: Vitamin D deficiency and insufficiency occur frequently in youth with HIV infection, particularly among those receiving the antiretroviral drug efavirenz. Optimal vitamin D dosing for treatment is unclear. Objective: Our objective was to evaluate safety and measure change in 25-hydroxyvitamin D (25-OHD) concentration from baseline to study wk 4 and 12 during treatment with vitamin D3, 50,000 IU monthly. Design, Setting, and Participants: We conducted a randomized double-blind, placebo-controlled multicenter trial of HIV-infected youth ages 18-24 yr, with viral load below 5000 copies/ml, on stable antiretroviral therapy. Intervention: Intervention included vitamin D3, 50,000 IU (n = 102), or matching placebo (n = 101) administered in three directly observed oral doses at monthly intervals. Results: At baseline, mean (SD) age was 20.9 (2.0) yr; 37% were female and 52% African-American, and 54% were vitamin D deficient/insufficient (25-OHD < 20 ng/ml), with no randomized group differences. Of evaluable participants vitamin D deficient/insufficient at baseline who were administered vitamin D, 43 of 46 (93%) had sufficient 25-OHD by wk 12. Vitamin D supplementation increased 25-OHD serum concentration from a baseline of 21.9 (13.3) to 35.9 (19.1) ng/ml at wk 12 (P < 0.001) with no change for placebo. Although use of the antiretroviral efavirenz was associated with lower baseline 25-OHD concentration, efavirenz did not diminish the response to vitamin D supplementation. There was no treatment-related toxicity. Conclusions: Supplementation with vitamin D 3 50,000 IU monthly for three doses was safe. Increases in 25-OHD occurred in treated participants regardless of antiretroviral regimen.

Original languageEnglish (US)
Pages (from-to)4004-4013
Number of pages10
JournalJournal of Clinical Endocrinology and Metabolism
Issue number11
StatePublished - Nov 2012
Externally publishedYes

ASJC Scopus subject areas

  • Biochemistry
  • Clinical Biochemistry
  • Endocrinology
  • Biochemistry, medical
  • Endocrinology, Diabetes and Metabolism


Dive into the research topics of 'Serum 25-hydroxyvitamin D response to vitamin D<sub>3</sub> supplementation 50,000 IU monthly in youth with HIV-1 infection'. Together they form a unique fingerprint.

Cite this